Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

Table 3 Utility scores

Parameters	Utility	Time with Disease	Ranges	References
Screening Pap	0.98	1 months	2 weeks – 2 months	Myers et al³⁹ and Insinga et al⁴⁰
ASCUS pap	0.94	1 month	2 weeks-2 months
>= LSIL pap	0.91	2 months	1–4 months
Warts	0.91	2 months	1–4 months
CIN 1	0.91 0.96	2 months 10 months	2–4 months 0–10 months
CIN 2–3	0.87	2 months	1–4 months
FIGO I	0.76	5 years	1–5 years
FIGO II	0.67	5 years	1–5 years
FIGO III	0.67	5 years	1–5 years
FIGO IV	0.67	5 years	1–5 years

ISSN: 1478-7547